SCHEMBL21458588

SCHEMBL21458588

CCOC(=O)COCCOCCOCCOCCOCCOC1CCN(C(=O)O)C(C(C)(C)C)C1

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
LIPG Q9Y5X9 2/20 0.34
ITGB3 P05106 3/20 0.32
ITGA2B P08514 3/20 0.32
LIPC P11150 1/20 0.32
HRH1 P35367 1/20 0.31
KMT2A Q03164 1/20 0.31
EPHX2 P34913 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28516435 0.99 LIPG (0.34) LIPGITGB3ITGA2BLIPCHRH1
SCHEMBL21070250 0.78 LIPG (0.35) LIPG
SCHEMBL22973217 0.77 LIPG (0.35) LIPGITGB3ITGA2BLIPCHRH1
SCHEMBL29061084 0.77 AGTR2 (0.48) LIPGKMT2AEPHX2
SCHEMBL21997606 0.76 AGTR2 (0.38) LIPGLIPCKMT2A
SCHEMBL30936775 0.76 AGTR2 (0.49) LIPGKMT2AEPHX2
SCHEMBL17888588 0.75 AGTR2 (0.31)
SCHEMBL21997474 0.74 DPP4 (0.33) ITGB3ITGA2B
SCHEMBL21458566 0.74 GPR119 (0.41) KMT2A
SCHEMBL21459014 0.74 GPR119 (0.41) KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552783-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-02-17 US disclosed
US-20220402907-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE YALE UNIVERSITY 2022-12-22 US disclosed
US-11161841-B2 Modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2021-11-02 US disclosed
US-20190315732-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2019-10-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190315732-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, CRBN, VHL LIPG 858/4885ITGB3 4282/4885ITGA2B 3916/4885
US-20220402907-A1 MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE MDM2, CRBN, VHL LIPG 858/4885ITGB3 4282/4885ITGA2B 3916/4885
US-12552783-B2 Modulators of proteolysis and associated methods of use CRBN, ADRM1, MDM2 LIPG 1725/4885ITGB3 3075/4885ITGA2B 3302/4885
US-11161841-B2 Modulators of proteolysis and associated methods of use MDM2, CRBN, VHL LIPG 858/4885ITGB3 4282/4885ITGA2B 3916/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.